Aileron Therapeutics, Inc
https://www.aileronrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aileron Therapeutics, Inc
Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
Venture Funding Deals: Two Companies With China Ties Raise $260m Each
Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.
IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose
With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?
IPO Update: New Offerings Outperform As September Ends With Biopharma Trifecta
There have been 29 IPOs in the US through the third quarter of 2017 with an average return of 35.2%, including three offerings on the same day – Deciphera, Nightstar and NuCana – near the end of September.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Renegade Therapeutics